LADENBURG THALM/SH SH downgraded shares of Microbot Medical (NASDAQ:MBOT) from a buy rating to a hold rating in a research note published on Monday morning, MarketBeat.com reports. They currently have $1.75 price target on the biotechnology company’s stock. The analysts noted that the move was a valuation call.
Several other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Microbot Medical from a hold rating to a sell rating in a research note on Wednesday, August 29th. ValuEngine cut shares of Microbot Medical from a buy rating to a hold rating in a research note on Tuesday, October 2nd.
NASDAQ MBOT opened at $2.16 on Monday. Microbot Medical has a twelve month low of $2.14 and a twelve month high of $18.60.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.